Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?

Investors are facing a decision between investing in Axsome Therapeutics or Moderna, two prominent biotech firms with distinct approaches and growth prospects. Axsome Therapeutics focuses on developing and commercializing therapies for central nervous system conditions, including major depressive disorder, excessive daytime sleepiness, and acute migraines.

The company reported a 54% increase in revenue to approximately $865.3 million in the 12 months ending September 30, 2026, despite a net loss of around $157.3 million and a negative net margin of 18.2%. Its debt-to-equity ratio is relatively high at 2.7x, indicating a higher level of debt financing.

Moderna, on the other hand, leverages its proprietary messenger RNA platform to create a diverse pipeline of vaccines and therapeutics. The company has successfully moved beyond its initial COVID-19 success to launch products for respiratory syncytial virus and advance candidates in oncology. In the same 12-month period, Moderna reported revenue of about $2.5 billion, a 13.7% increase from the previous year.

However, the company remains in the red with a net loss of approximately $2.8 billion and a negative net margin of 110.5%. Moderna's debt-to-equity ratio is much lower at 0.2x, suggesting a stronger financial position with less reliance on debt.

While Axsome Therapeutics trades at a significantly lower valuation multiple compared to Moderna, both companies face varying degrees of competition and risks. Axsome's revenue growth is more limited but could expand with the introduction of additional therapies. Moderna's larger revenue base comes with higher operating expenses and financial risk, given its continued investment in R&D and dependence on complex manufacturing processes.

Ultimately, the choice between these two biotech innovators may depend on an investor's risk tolerance and growth expectations for specialized versus broad-spectrum therapeutic applications.